Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 29 September

Grady Wulff
September 29, 2022

Morning Bell 28 September

Grady Wulff
September 28, 2022

Closing Bell 27 September

Sophia Mavridis
September 27, 2022

Morning Bell 27 September

Sophia Mavridis
September 27, 2022

Closing Bell 26 September

Grady Wulff
September 26, 2022

Morning Bell 26 September

Grady Wulff
September 26, 2022

Morning Bell 23 September

Sophia Mavridis
September 23, 2022

Closing Bell 21 September

Grady Wulff
September 21, 2022

Morning Bell 21 September

Grady Wulff
September 21, 2022

Closing Bell 20 September

Grady Wulff
September 20, 2022

Morning Bell 20 September

Paulina Peters
September 20, 2022

Closing Bell 19 September

Grady Wulff
September 19, 2022